histone H3.3-K27M neoantigen vaccine (University of Florida)

The histone H3.3-K27M neoantigen vaccine is an investigational peptide-based immunotherapy designed to treat diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric brainstem tumor. The vaccine targets a specific somatic mutation (lysine 27 to methionine, K27M) in the H3F3A gene, which encodes the histone H3.3 variant. This mutation is present in approximately 80% of DIPG cases and creates a unique neoantigen not found in healthy cells. The vaccine consists of a synthetic peptide encompassing the mutation site, which is presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). This presentation activates neoantigen-specific cytotoxic T lymphocytes (CTLs) that are intended to recognize and eliminate H3.3-K27M-expressing tumor cells. In clinical trials, such as the Phase I ENACTING study, the vaccine is typically administered via subcutaneous injection in combination with an adjuvant (like poly-ICLC) and standard-of-care radiotherapy to enhance the anti-tumor immune response.

Other names

histone H3.3-K27M neoantigen vaccine therapyH3.3-K27M peptide vaccineH-3.3-K27M peptide vaccineH 3.3-K27M peptide vaccineH3.3K27M vaccineH-3.3K27M vaccineH 3.3K27M vaccineH3.3-K27M neoantigen vaccineH-3.3-K27M neoantigen vaccineH 3.3-K27M neoantigen vaccine